Sign in

CIK 0001398733

  • Non-accelerated filer
  • Smaller reporting company

Aquestive Therapeutics, Inc.

Sign in to watch
Ticker
AQST
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
208623253
Phone
+1 908-941-1900
Business address
184 LIBERTY CORNER ROAD, SUITE 305, WARREN, NJ
Former names
MonoSol Rx, Inc.
  1. 4 Open-market sale Chief Innovation/Tech Officer sold 35,000 shares at $6.75 ($236,250)
  2. 4 Open-market sale Chief Innovation/Tech Officer sold 40,792 shares at $6.50 ($265,148)
  3. 3 Insider Initial Statement of Ownership
  4. 4 Gift CEO and President gave 2,000 shares (gift)
  5. 4 Open-market sale SVP-Chief Financial Officer sold 3,000 shares at $8.00 ($24,000)
  6. 4 Shares withheld for taxes Chief Innovation/Tech Officer gave up 94 shares (to pay taxes)
  7. 4 Shares withheld for taxes CEO and President gave up 148 shares (to pay taxes)
  8. 4 Derivatives Options or other derivatives
  9. 4 Derivatives Options or other derivatives
  10. 4 Derivatives Options or other derivatives
  11. 4 Derivatives Options or other derivatives
  12. 4 Derivatives Options or other derivatives
  13. 4 Derivatives Options or other derivatives
  14. 4 Open-market sale CEO and President sold 50,000 shares at $5.11 ($255,310)
  15. 4 Shares withheld for taxes Chief Innovation/Tech Officer gave up 4,132 shares (to pay taxes)
  16. 4 Shares withheld for taxes CEO and President gave up 6,492 shares (to pay taxes)
  17. 4 Open-market sale Chief Innovation/Tech Officer sold 40,000 shares at $5.00 ($200,000)
  18. 4 Open-market sale Chief Innovation/Tech Officer sold 80,000 shares at an average $3.85 ($308,000)
  19. 4 Open-market sale Chief Innovation/Tech Officer sold 40,000 shares at $4.50 ($180,000)
  20. 4 Shares withheld for taxes CEO and President gave up 99 shares (to pay taxes)

Page 11 of 17 · 326 filings